SEPN

Septerna, Inc.

BS score 39.6LOWPHASE1 · mkt cap $1.12B · rev ttm $46.0M

drug hypothesis

SEP-479 modulates Not specified to treat Not specified - Phase 1 study in healthy volunteers.

moa:Not specified

score breakdown

trial design32

base rate disconnect27

language red flags80

composite39.6

valuation analysis

market cap$1.12B

revenue ttm$46.0M

phasePHASE1

historical base rate8%

disconnect ratio0.9x

lead trialNCT07433179

meta

cik0001984086

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1, randomized, triple-blind study in 150 healthy adult participants to evaluate single and multiple doses. Not placebo-controlled. Primary follow-up up to approximately 2 months.

primary endpoint:Frequency of treatment emergent adverse events (safety/tolerability)

claimed differentiation

Not provided - No business section text included in filing

language red flags

Insufficient information provided to assess - business section text appears to be missing or empty
No target, mechanism of action, or indication details disclosed
No preclinical or clinical data referenced
No stated risks or differentiation claims visible in available materials